Thymidylate synthase (TS) is an essential enzyme in proliferating cells and an important target for several chemotherapeutics. Several TS gene polymorphisms correlate with variable TS expression: a double (2R) and triple (3R) 28-bp repeat element, a G to C substitution of the 3R allele and a 6 bp variation in 3 0 UTR. We have previously shown that childhood acute lymphoblastic leukemia (ALL) patients who are homozygous for the 3R allele had reduced event-free survival (EFS) probabilities. Here, we analyzed all three polymorphisms in an extended group of ALL patients (n ¼ 259). The effect of the 3R homozygosity on ALL outcome was confirmed (P ¼ 0.006), whereas 6 bp polymorphism did not influence EFS when analyzed separately. No significant difference among 3R3R genotype subgroups, as defined by a G to C substitution, was observed. The haplotype analysis revealed the higher frequency of the 3RC/6 bp þ haplotype (P ¼ 0.04) and the protective role of the 2R/6b pÀ (P ¼ 0.04). Consequently, homozygosity for the 6 bpÀ allele appeared to reduce an event-predisposing effect of 3R variant. Although of importance for translation into the clinical practice, these findings need confirmation in larger studies.
INTRODUCTION
Thymidylate synthase (TS) is a key enzyme in the nucleotide biosynthesis and important target of several chemotherapeutics. TS provides the only source for de novo thymidylate production by catalyzing the methylation of deoxyuridine monophosphate (dUMP) to deoxythymidine monophosphate (dTMP). 1 TS is efficiently inhibited by the uracil analog, 5-fluorouracil (5-FU), used for many years as a treatment for a variety of cancers. 2 Cytotoxic effect of the antifolate methotrexate (MTX) involves TS inhibition as well. MTX is a key drug of leukemia treatment and is one of the most widely prescribed drugs for the treatment of rheumatoid arthritis (RA). 3, 4 TS is inhibited indirectly, by MTXrelated depletion of the folate cofactors, and directly, by MTX polyglutamates (MTX (Glu) n ). 5 In spite of the proven efficiency, great interpatient variability in the clinical response to these drugs is observed. 6, 7 TS expression has been reported to correlate with the responses to TS-directed chemotherapeutics. [6] [7] [8] Subsequent discovery of different polymorphisms in the TS gene, which correlate with altered TS expression, has led to the hypothesis that TS gene variants might be useful predictors of the response to drugs interfering with TS activity. Indeed various studies have shown that TS genotypes are associated with clinical efficacy in terms of response and survival to 5-FU-or MTX-based therapy, as shown in colorectal carcinoma, gastric cancer, leukemia and RA. [9] [10] [11] [12] Several polymorphisms are described in the TS gene. A tandem repeat sequence was identified in the enhancer element of 5 0 UTR region. 13, 14 It has been shown to contain variable numbers of a 28-bp repeat element with the double (2R) and triple repeat (3R) alleles being the most frequent.
The repeat element appears to function as an enhancer because in vitro studies showed increased TS expression and translation efficiency associated with the 3R allele compared to that of the 2R allele. 13, 15 These findings have been confirmed in the clinical setting by showing higher TS mRNA and protein levels in 3R homozygous patients compared to 2R homozygotes. 10, 16, 17 Recent studies showed that the impact of 3R allele on TS transcription is related to an additional upstream stimulatory factor (USF) proteinbinding site compared to that of the 2R variant. 18, 19 In addition, a G to C polymorphism in the second repeat element of the 3R allele (3RC vs 3RG) changes a critical residue in the USF-binding site, abolishing its ability to complex with the USF protein. As a result, a 3RC construct displayed in vitro a similar transcriptional activity and translational efficiency to that of a 2R allele. And finally, a polymorphism within the TS gene, consisting of a 6 bp deletion in the 3 0 UTR region, has been discovered through searching the public expressed sequence tag database. 20 In vitro analysis indicated that the 6 bp polymorphism is associated with decreased mRNA stability. 21 Lower mRNA levels in homozygous 6 bpÀ/6 bpÀ colon cancer patients, compared to 6 bp þ /6 bp þ individuals, further supported this finding. 21 We have previously shown that 3R/3R homozygous individuals were significantly over-represented in the event-positive group in childhood acute lymphoblastic leukemia (ALL) patients and had a shorter event-free survival (EFS) when compared to other genotypes. 9 Here we extended the analysis to a larger patient population and to longer time of patients' follow-up. Furthermore, in the light of new data regarding TS gene variability, we analyzed the impact of all three TS polymorphisms on EFS probabilities in ALL patients.
RESULTS
The frequencies of 28-bp repeat variation and 6 bp þ /À polymorphism in ALL children with and without event are given in Table 1 . Individuals who are homozygous for 3R allele were found at a higher frequency in the event-positive group. Kaplan-Meier estimates showed that 3R3R individuals had a lower probability of 5-year post-treatment EFS compared to other genotype groups (P ¼ 0.006, Figure 1) . Accordingly, individuals with this genotype were at a higher risk of event compared to 2R/2R and 2R/3R patients (hazard ratio (HR) ¼ 2.1, 95% CI, 1.2-3.7, P ¼ 0.006). When patients and disease characteristics (see Materials and methods) were entered together with the TS repeat genotype in the Cox regression model, HR estimates for 3R/3R individuals were not changed (HR ¼ 2.5, 95% CI, 1.3-4.8, P ¼ 0.005). Further analysis of disease-free survival (DFS, n ¼ 49) showed a similar result for TS 3R homozygosity, as in EFS analysis (P ¼ 0.006), whereas no association was found with overall survival (OS, n ¼ 26).
Following the hypothesis that the G to C substitution can modulate the effect of TS 3R variant, we analyzed the association between 2R, 3RC and 3RG genotypes and EFS probabilities in the same group of patients. The respective 
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193 (31) p=0.006 Figure 1 Kaplan-Meier estimates of event-free survival (EFS) for ALL patients in the function of 3R3R genotypes. EFS curves for patients who are positive ((3R/3R) þ , full line) or negative ((3R/ 3R)À, dotted line) for TS 3R/3R genotype. The genotype and the number of patients for each curve, numbers of individuals with an event (in the parenthesis), as well as the P-value, estimated by logrank test for the survival differences between the patients groups, are indicated on the plot. Tic marks denote patients without an event (censored cases).
genotype frequencies in children with and without an event are given in Table 2 . Individuals with 3R/3R genotype subgroups (3RC/3RC, 3RC/3RG and 3RG/3RG) were all found at increased frequencies in the event-positive as compared to the event-negative group. When EFS was analyzed, a trend was seen across genotype subgroups with 3RG/3RG homozygotes having the worst outcome (P for trend ¼ 0.003, Figure 2 ). However, all three 3R/3R subgroups contributed to the increased risk of event: there was no significant difference between them (P ¼ 0.4 when 3RG/3RG genotypes were compared to 3RG/3RC and 3RC/3RC individuals); the association with EFS was retained if only 3RC/3RC and 3RC/3RG genotypes are compared to those containing 2R allele (P ¼ 0.01, data not shown).
We further assessed the combined effect of the 28-bp repeat and 6 bp þ /À polymorphisms. Linkage disequilibrium was observed (P ¼ 0.002) and four possible haplotypes (2R6 bp þ , 2R6 bpÀ, 3R6 bp þ and 3R6 bpÀ) were distinguished. When the haplotype frequencies were compared between groups with and without an event, the haplotype 2R6 bpÀ had the lower frequency in the event-positive group (Table 3 , P ¼ 0.04). Stratification of 3R3R individuals by 6 bp þ /À genotypes (Table 4) revealed that 3R3R homozygotes with at least one 6 bp þ allele had the higher frequency among children with an event (36.6 vs 17.2% for the combined 6 bp þ /6 bp þ and 6 bp þ /6 bpÀ genotypes), whereas similar frequencies (3.8 vs 3.4%) between the event and nonevent group were noted for individuals with the 3R/3R genotype that are 6 bpÀ homozygotes. A further reduction of the 5-year post-treatment EFS probabilities to 57% (P ¼ 0.001, Figure 3 ) was observed for 3R3R individuals with the 6 bp þ allele compared to 63% when all 3R3R individuals were taken together (see Figure 1 ). Multivariate analysis did not change this result.
And finally, we analyzed the combined effect of all three TS polymorphisms and resulting six haplotypes, 2R6 bp þ , 2R6 bpÀ, 3RC6 bp þ , 3RC6 bpÀ, 3RG6 bp þ and 3RG6 bpÀ (Po0.0005 in favor of linkage disequilibrium). Comparing haplotype frequencies between children with and without an event pointed to already observed lower frequency of a The frequency of 2R6 bpÀ haplotype was significantly lower in the event compared to the nonevent group (P ¼ 0.04). 
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EFS probability Time (months) Figure 2 Kaplan-Meier estimates of EFS for ALL patients in the function of 28-bp repeat variation genotypes following stratification of 3R allele on 3RC and 3RG. EFS curves are given for 2R carriers (2R*) and each 3R/3R subgroup (3RG/3RG, 3RC/3RG, 3RC/3RC). The genotype and the number of patients in each curve differentiated by the line type, numbers of individuals with an event (in the parenthesis), as well as the P-value for trend are indicated on the plot. Tic marks denote patients without event (censored cases). The color figure is available online. Green, blue, yellow and red line indicate 3RG/3RG, 3RC/3RG, 3RC/3RC and 2R* genotypes, respectively. Figure 2 .
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In addition, the 3RC6 bp þ haplotype was found more frequently in the event-positive group (P ¼ 0.04), suggesting its contribution to the higher prevalence of 3R3R/6 bp þ genotypes observed in the preceding analytical step among patients with an event.
No significant association between genotypes of the 28-bp repeat and 6 bp polymorphisms, analyzed separately or combined, and the MTX dosage or frequency of weeks with MTX dose reduction or withdrawal due to drug-related toxicity, was observed. Likewise, genotype groups following diversification of 3R repeat in 3RC and 3RG alleles were not significantly different. Although not significant, it is worth noting that the mean frequency of weeks when MTX was reduced or withheld was lower in 3RG/3RG individuals than in other genotype groups (3.4 vs 10.1%, data not shown).
DISCUSSION
The clinical consequences of TS 28-bp repeat polymorphism have been described in several studies. They appear to be consistent and follow the pattern predicted by the functional studies. Homozygous 3R/3R individuals had reduced EFS probabilities in childhood ALL patients (Krajinovic et al 9 and this study), whereas carriers of 2R variant seem to be more prone to drug side effects. 22 Likewise, RA patients that are homozygous for the 3R allele required higher dose of MTX compared to 2R/2R individuals. 12 In contrast, a better clinical response, as based on a lower score of disease activity, has been observed in homozygous 2R patients. 23 The same genotype-dependent response was observed for 5-FU, with a lower response rate in 3R/3R individuals 11, 16, 24, 25 and higher incidence of side effects in 2R/2R patients. 16, 26 A G to C substitution diversifies 3R in 3RC and 3RG alleles. As based on in vitro assays, resulting genotypes could be classified into the groups with low and high expression. 18, 19 The low expression group contains genotypes with 2R or 3RC alleles and the high-expression group contains those with 3RG variant. Two studies have addressed the predictive role of TS genotypes following this classification. Patients with gastric or colorectal cancer with low expression genotypes responded better to 5-FU treatment. 19, 27 In our study, a trend across genotypes was observed when 2R containing genotypes and 3R/3R subgroups were included in the analysis, with 3RG/3RG individuals having the worst outcome, as expected. However, the EFS probabilities in 3RC/3RG and 3RC/3RC individuals were also reduced compared to 2R carriers and did not significantly differ from that of 3RG homozygotes. Therefore, 3RC/3RC individuals did not have the same response rate as 2R/2R homozygotes, as would be expected from the number of USF-binding sites. The role or 3RC allele as an eventpredisposing factor was further confirmed by haplotype analysis. Given the opposite effect of 3R and 6 bpÀ alleles on TS mRNA concentrations, 21 it could be expected that 6 bp deletion antagonizes the effect of the 3R allele or accentuates that of 2R. Indeed, we observed lower frequency of the 2R6 bpÀ haplotype among children with an event, whereas the impact of 3R homozygosity on the reduction of EFS probabilities was only seen in individuals that are also 6 bp þ carriers. Few studies addressed the impact of 6 bp þ /À polymorphism alone or combined with the 28-bp repeat variation on the outcome of diseases treated with MTX or 5-FU. In accordance with our observation, a better response to MTX treatment was reported in RA patients that are homozygous for 6 bp deletion. 12 However, contrary to this, an increased risk of disease progression in refractory colorectal cancer patients who received 5-FU was associated with Figure 3 Kaplan-Meier estimates of event-free survival (EFS) for ALL patients following stratification of 3R3R genotypes by 6 bp þ /À polymorphism. The lower curve (full line) represents EFS for patients who are both homozygous for 3R variant and the carriers of 6 bp þ allele ((3R3R/6 bp þ ) þ ). The upper curve (dotted line) represents EFS for individuals without these TS genotypes ((3R3R/ 6 bp þ ) À ). The genotype and the number of patients in each curve, numbers of individuals with an event (in the parenthesis), as well as the P-value, estimated by log-rank test for the survival differences between the patients groups, are indicated on the plot. Tic marks denote patients without event (censored cases). The frequency of 3RC6 bp+ haplotype was significantly higher in the event compared to nonevent group (P ¼ 0.04).
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TS polymorphisms and childhood ALL outcome M Krajinovic et al the 6 bpÀ allele. 28 Likewise, a higher risk of severe side effects was associated with 2R variant with the 6 bp þ allele (and not 6 bpÀ as would be expected). 26 We did not observe a significant association between the TS genotypes and MTX toxicity in the group of childhood ALL patients studied, at least not to the extent that it would lead to MTX withdrawal or dose reduction. It should be, however, kept in mind that the influence of TS alleles cannot be completely ruled out due to the small size of different genotype subgroups. For example, we noticed that the mean frequency of weeks with MTX reduction or withdrawal was lower in 3RG/3RG individuals than in other genotype groups, suggesting that these individuals might be less prone than others to the drug side effects. Further analyses of MTX toxicity beyond MTX dose as well as in the larger patient cohorts are needed.
Our study sheds additional insight on the role of TS polymorphisms in ALL outcome. It appears that 6 bp þ /À polymorphism can modulate the effect of a 28-bp repeat element in the manner that is expected from the functional effects of these variants. In contrast, the effect of 3RC on EFS probability did not follow the pattern predicted in vitro and was also associated with reduced EFS probabilities in our group of childhood ALL patients. Other polymorphisms of the TS gene or polymorphisms in other genes of the folate pathway might account for this discrepancy. Given the relatively low sample size of our patient population, replication of this finding in larger patient groups is required. Further studies are also needed to understand the joint effect of TS polymorphisms on mRNA and protein expression as well as the involvement of control mechanisms by which TS expression is regulated.
MATERIALS AND METHODS
Study Population
The patients (n ¼ 259) included in this study are children of European descent diagnosed with ALL at Sainte-Justine Hospital, Montreal, Canada, between 1989 and July 2002, treated with the multiagent chemotherapeutic protocols DFCI 87-01, 91-01, 95-01 or 2000-01 of the Dana-Farber Cancer Institute. 9 The details of the MTX administration are given elsewhere. 29 The distribution of prognostic factors at diagnosis (sex, age, white blood cell (WBC) count, ALL immunophenotype, treatment protocol, risk group and DNA index) was used in Cox's regression analysis (see Statistics) to estimate the independent effect of genotypes. For this, patients were categorized according to relapse risk prediction (boys or girls; age below 1 year, 1-10 and above 10; WBC below or above of 50 Â 10 9 ; B-or T-cell type; standard or high and very high risk and DNA index above or below 1.16, corresponding to 50 chromosomes). 29 Children who relapsed or had a fatal outcome due to the disease were defined to have had an event. Information concerning the withdrawal, reduction and increase of MTX dose carried out according to the treatment protocols was available for 192 patients. Respective data were retrieved for each week of the maintenance phase of the treatment for which such information was available. The change from the dose that would have been received if toxic episode did not occur was verified in two independent sources (institutional database for DFCI treatment protocols and patients' medical charts). Patient samples were obtained at diagnosis and at remission after informed consent. The Hospital Ethical Committee approved the study protocol.
Genotyping
The PCR products of the 5 0 UTR genomic segment, containing TS repeat polymorphisms and the G to C substitution, was analyzed by gel electrophoresis for the presence of the 28-bp repeat genotypes and by subsequent HaeIII digestion for the genotypes of the G to C polymorphism. The presence or absence of the 6 bp (TTAAAG) sequence in 3 0 UTR was screened by allele-specific oligonucleotide (ASO) hybridization. For that the PCR products were dot-blotted in duplicate on a nylon membrane and assayed for the presence of respective variants. 30 ASO probes specific for the 6 bp þ (gaactttaaagttatag) and 6 bpÀ (ggttatgaactttatag) alleles (the variable sequence region is underlined) were designed and hybridized at 401C and 481C, respectively. DraI digestion of the PCR product 20 served as a control for the optimization of ASO genotyping.
DNA segments in 5 0 -and 3 0 UTRs encompassing polymorphic sites were amplified by PCR using 15 ng of genomic DNA, 0. /week) or the frequency of weeks with reduced or withheld doses of MTX, were correlated using Mann-Whitney or Kruskal-Wallis tests. When applicable, the weeks with missing data were excluded from the total number of weeks. The analyses were carried out using the SPSS statistical package (Version 10.0).
The estimates of linkage disequilibrium between TS polymorphisms as well as of maximum-likelihood estimates of haplotype frequencies in event and nonevent group were estimated by EH linkage utility software. 31 The estimates were then used to calculate the number of haplotypes from the total number of chromosomes in each group of patients.
